Jiangsu Hengrui Medicine Co., Ltd.

600276

CNE0000014W7

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Sector

Pharmaceuticals

Calendar

2024-04-17 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Hengrui Medicine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.56 CNY

Average target price

57.52 CNY

Spread / Average Target

+29.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU HENGRUI MEDICINE CO., LTD.	-1.48%	39.14B
ELI LILLY AND COMPANY	+28.10%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.84%	356B
MERCK & CO., INC.	+14.71%	320B
ABBVIE INC.	+4.88%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.77%	142B

Other Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
44.56 ^CNY	+1.07%		-1.85%	-1.48%

Apr. 11	Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	MT
Apr. 10	China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs	MT

Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	Apr. 11	MT
China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs	Apr. 10	MT
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs	Apr. 09	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Apr. 01	CI
Hengrui Pharma Gets Nod for Injectable Cancer Drug Trial	Mar. 27	MT
Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs	Mar. 19	MT
Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral	Mar. 15	MT
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE
Hengrui Pharma Gets Green Light to Trial Tumor Drug Combination	Feb. 29	MT
Hengrui Pharma Gets China Nod to Trial Combo Treatment for Breast Cancer	Feb. 28	MT
US FDA Gives Fast Track Designation to Hengrui Pharma's Lymphoma Drug	Feb. 22	MT
Hengrui Pharma's Unit Gets Nod to Trial Adebelimab Injection	Feb. 22	MT
GSK completes acquisition of Aiolos Bio for up to $1.4 bln	Feb. 15	RE
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	Feb. 07	CI
Cancer Drug of Hengrui Pharmaceuticals' Unit Placed in China's List of Breakthrough Therapy Drugs; Shares Climb 4%	Feb. 05	MT
Hengrui Pharmaceuticals Gets Nod for Taglidine Fumarate Injection	Feb. 01	MT
Hengrui Pharmaceuticals' Subsidiary Gets US FDA's Nod for Tacrolimus Capsules	Jan. 30	MT
Hengrui Pharma's Unit Gets Nod to Trial Adbelimab Injection	Jan. 17	MT
Hengrui Pharmaceuticals, Subsidiary Get Chinese Drug Regulator's Nod for Two Drugs	Jan. 08	MT
Chinese Shares Finish Lower Ahead of US Jobs Data; Hengrui Pharma Slides 4% on New Drug Approvals	Jan. 05	MT
China money managers rush to create funds tracking new A50 index	Jan. 03	RE
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Jan. 02	CI
Hengrui Pharmaceuticals’ Cancer Drug Receives Fast Track Designation From US FDA	Jan. 02	MT
Hengrui Pharma Gets Nod for Clinical Trial of Two Drugs	Dec. 21	MT
Hengrui Pharma Gets Regulatory Nod to Trial Proline Tablets as Kidney Disease Drug	Dec. 15	MT